{"id":10488,"date":"2019-10-25T12:29:12","date_gmt":"2019-10-25T06:59:12","guid":{"rendered":"https:\/\/www.rootsanalysis.com\/blog\/?p=10488"},"modified":"2026-07-27T13:27:08","modified_gmt":"2026-07-27T07:57:08","slug":"cell-therapy-market-update-maxcyte-advances-phase-i-clinical-trial-of-lead-mrna-based-cell-therapy","status":"publish","type":"post","link":"https:\/\/www.rootsanalysis.com\/blog\/cell-therapy-market-update-maxcyte-advances-phase-i-clinical-trial-of-lead-mrna-based-cell-therapy\/","title":{"rendered":"Cell Therapy Market Update: MaxCyte Advances Phase I Clinical Trial of Lead mRNA-based Cell Therapy"},"content":{"rendered":"<div class=\"wp-block-image\">\n<figure class=\"aligncenter size-large is-resized\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"160\" src=\"https:\/\/www.rootsanalysis.com\/blog\/wp-content\/uploads\/2023\/09\/MAXCYTE_Logo-1024x160.webp\" alt=\"Maxcyte_Logo\" class=\"wp-image-16262\" style=\"object-fit:contain;width:600px;height:95px\" srcset=\"https:\/\/www.rootsanalysis.com\/blog\/wp-content\/uploads\/2023\/09\/MAXCYTE_Logo-1024x160.webp 1024w, https:\/\/www.rootsanalysis.com\/blog\/wp-content\/uploads\/2023\/09\/MAXCYTE_Logo-300x47.webp 300w, https:\/\/www.rootsanalysis.com\/blog\/wp-content\/uploads\/2023\/09\/MAXCYTE_Logo-768x120.webp 768w, https:\/\/www.rootsanalysis.com\/blog\/wp-content\/uploads\/2023\/09\/MAXCYTE_Logo-1536x240.webp 1536w, https:\/\/www.rootsanalysis.com\/blog\/wp-content\/uploads\/2023\/09\/MAXCYTE_Logo-2048x320.webp 2048w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><figcaption class=\"wp-element-caption\">MaxCyte<\/figcaption><\/figure>\n<\/div>\n\n\n<p class=\"wp-block-paragraph\">MaxCyte, the global Cell Therapy, and life sciences company, announced the initiation of dosing in the third cohort of patients of MaxCyte&#8217;s Phase I clinical trial (<a href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03608618\">NCT03608618<\/a>) with the next higher cell dose of MCY-M11.&nbsp;The dose-escalation trial is evaluating the safety and tolerability, as well as preliminary efficacy, of MCY-M11 administered intraperitoneally across a series of ascending dose-level cohorts.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>What is MCY-M11<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">MCY-M11 is a\u00a0mesothelin-targeting chimeric antigen receptor (CAR) therapy. It is a wholly-owned, non-viral mRNA-based cell therapy candidate from <a href=\"https:\/\/investors.maxcyte.com\/news-releases\/news-release-details\/maxcyte-inc-present-carmatm-platform-two-upcoming-industry\">MaxCyte&#8217;s CARMA platform<\/a>. The therapy is currently being tested in individuals with relapsed\/refractory ovarian cancer and peritoneal mesothelioma.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>What were the results in the first two cohorts<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">According to the company, in the first two cohorts, the infusion of MCY-M11 has been well-tolerated in all patients treated. No dose-limiting toxicities, infusion-related adverse events, on-target or off-target toxicities, or other unwanted events were observed.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">For additional details on KOL opinion about the cell therapies market, check the blog <a href=\"https:\/\/www.rootsanalysis.com\/blog\/t-cell-immunotherapies-market-kol-interviews-highlight-key-trends\/\">Market report for Cell Therapy<\/a>.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n","protected":false},"excerpt":{"rendered":"<p>MaxCyte, the global Cell Therapy, and life sciences company, announced the initiation of dosing in the third cohort of patients of MaxCyte&#8217;s Phase I clinical trial (NCT03608618) with the next higher cell dose of MCY-M11.&nbsp;The dose-escalation trial is evaluating the safety and tolerability, as well as preliminary efficacy, of MCY-M11 administered intraperitoneally across a series [&hellip;]<\/p>\n","protected":false},"author":21,"featured_media":17273,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[118],"tags":[153,330],"class_list":["post-10488","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cell-therapy","tag-cell-therapy","tag-maxcyte"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Cell Therapy Market Update: MaxCyte Advances Phase | Blog<\/title>\n<meta name=\"description\" content=\"MaxCyte, the global Cell Therapy, and life sciences company, announced the initiation of dosing in the third cohort of patients..\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.rootsanalysis.com\/blog\/cell-therapy-market-update-maxcyte-advances-phase-i-clinical-trial-of-lead-mrna-based-cell-therapy\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cell Therapy Market Update: MaxCyte Advances Phase | Blog\" \/>\n<meta property=\"og:description\" content=\"MaxCyte, the global Cell Therapy, and life sciences company, announced the initiation of dosing in the third cohort of patients..\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.rootsanalysis.com\/blog\/cell-therapy-market-update-maxcyte-advances-phase-i-clinical-trial-of-lead-mrna-based-cell-therapy\/\" \/>\n<meta property=\"og:site_name\" content=\"Blog\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/RootsAnalysis\/\" \/>\n<meta property=\"article:published_time\" content=\"2019-10-25T06:59:12+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-27T07:57:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.rootsanalysis.com\/blog\/wp-content\/uploads\/2019\/10\/RootsAnalysis_FeaturedImage_Medical_Devices.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"150\" \/>\n\t<meta property=\"og:image:height\" content=\"150\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"Gaurav Chaudhary\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@RootsAnalysis\" \/>\n<meta name=\"twitter:site\" content=\"@RootsAnalysis\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Gaurav Chaudhary\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/cell-therapy-market-update-maxcyte-advances-phase-i-clinical-trial-of-lead-mrna-based-cell-therapy\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/cell-therapy-market-update-maxcyte-advances-phase-i-clinical-trial-of-lead-mrna-based-cell-therapy\\\/\"},\"author\":{\"name\":\"Gaurav Chaudhary\",\"@id\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/#\\\/schema\\\/person\\\/e8e0ebc31296140424e1e7fcc11331bc\"},\"headline\":\"Cell Therapy Market Update: MaxCyte Advances Phase I Clinical Trial of Lead mRNA-based Cell Therapy\",\"datePublished\":\"2019-10-25T06:59:12+00:00\",\"dateModified\":\"2026-07-27T07:57:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/cell-therapy-market-update-maxcyte-advances-phase-i-clinical-trial-of-lead-mrna-based-cell-therapy\\\/\"},\"wordCount\":184,\"publisher\":{\"@id\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/cell-therapy-market-update-maxcyte-advances-phase-i-clinical-trial-of-lead-mrna-based-cell-therapy\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/wp-content\\\/uploads\\\/2019\\\/10\\\/RootsAnalysis_FeaturedImage_Medical_Devices.webp\",\"keywords\":[\"Cell Therapy\",\"MaxCyte\"],\"articleSection\":[\"Cell Therapy\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/cell-therapy-market-update-maxcyte-advances-phase-i-clinical-trial-of-lead-mrna-based-cell-therapy\\\/\",\"url\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/cell-therapy-market-update-maxcyte-advances-phase-i-clinical-trial-of-lead-mrna-based-cell-therapy\\\/\",\"name\":\"Cell Therapy Market Update: MaxCyte Advances Phase | Blog\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/cell-therapy-market-update-maxcyte-advances-phase-i-clinical-trial-of-lead-mrna-based-cell-therapy\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/cell-therapy-market-update-maxcyte-advances-phase-i-clinical-trial-of-lead-mrna-based-cell-therapy\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/wp-content\\\/uploads\\\/2019\\\/10\\\/RootsAnalysis_FeaturedImage_Medical_Devices.webp\",\"datePublished\":\"2019-10-25T06:59:12+00:00\",\"dateModified\":\"2026-07-27T07:57:08+00:00\",\"description\":\"MaxCyte, the global Cell Therapy, and life sciences company, announced the initiation of dosing in the third cohort of patients..\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/cell-therapy-market-update-maxcyte-advances-phase-i-clinical-trial-of-lead-mrna-based-cell-therapy\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/cell-therapy-market-update-maxcyte-advances-phase-i-clinical-trial-of-lead-mrna-based-cell-therapy\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/cell-therapy-market-update-maxcyte-advances-phase-i-clinical-trial-of-lead-mrna-based-cell-therapy\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/wp-content\\\/uploads\\\/2019\\\/10\\\/RootsAnalysis_FeaturedImage_Medical_Devices.webp\",\"contentUrl\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/wp-content\\\/uploads\\\/2019\\\/10\\\/RootsAnalysis_FeaturedImage_Medical_Devices.webp\",\"width\":150,\"height\":150,\"caption\":\"This is a feature image for blog article Cell Therapy Market Update at Roots Analysis\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/cell-therapy-market-update-maxcyte-advances-phase-i-clinical-trial-of-lead-mrna-based-cell-therapy\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cell Therapy Market Update: MaxCyte Advances Phase I Clinical Trial of Lead mRNA-based Cell Therapy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/#website\",\"url\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/\",\"name\":\"Blog\",\"description\":\"Roots Analysis\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/#organization\",\"name\":\"Roots Analysis\",\"url\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/wp-content\\\/uploads\\\/2018\\\/11\\\/Roots-Analysis-High-Resolution-Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/wp-content\\\/uploads\\\/2018\\\/11\\\/Roots-Analysis-High-Resolution-Logo.jpg\",\"width\":205,\"height\":61,\"caption\":\"Roots Analysis\"},\"image\":{\"@id\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/RootsAnalysis\\\/\",\"https:\\\/\\\/x.com\\\/RootsAnalysis\",\"https:\\\/\\\/www.instagram.com\\\/rootsanalysis\\\/\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/roots-analysis\\\/\",\"https:\\\/\\\/www.pinterest.it\\\/analysis1340\\\/\",\"https:\\\/\\\/www.youtube.com\\\/channel\\\/UCwZF57vY1lnU0bNLej2zukg\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/#\\\/schema\\\/person\\\/e8e0ebc31296140424e1e7fcc11331bc\",\"name\":\"Gaurav Chaudhary\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/1661cbb4c9924618db626ec780a3daf2ebd251e93753c083102682dba715ded6?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/1661cbb4c9924618db626ec780a3daf2ebd251e93753c083102682dba715ded6?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/1661cbb4c9924618db626ec780a3daf2ebd251e93753c083102682dba715ded6?s=96&d=mm&r=g\",\"caption\":\"Gaurav Chaudhary\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cell Therapy Market Update: MaxCyte Advances Phase | Blog","description":"MaxCyte, the global Cell Therapy, and life sciences company, announced the initiation of dosing in the third cohort of patients..","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.rootsanalysis.com\/blog\/cell-therapy-market-update-maxcyte-advances-phase-i-clinical-trial-of-lead-mrna-based-cell-therapy\/","og_locale":"en_US","og_type":"article","og_title":"Cell Therapy Market Update: MaxCyte Advances Phase | Blog","og_description":"MaxCyte, the global Cell Therapy, and life sciences company, announced the initiation of dosing in the third cohort of patients..","og_url":"https:\/\/www.rootsanalysis.com\/blog\/cell-therapy-market-update-maxcyte-advances-phase-i-clinical-trial-of-lead-mrna-based-cell-therapy\/","og_site_name":"Blog","article_publisher":"https:\/\/www.facebook.com\/RootsAnalysis\/","article_published_time":"2019-10-25T06:59:12+00:00","article_modified_time":"2026-07-27T07:57:08+00:00","og_image":[{"width":150,"height":150,"url":"https:\/\/www.rootsanalysis.com\/blog\/wp-content\/uploads\/2019\/10\/RootsAnalysis_FeaturedImage_Medical_Devices.webp","type":"image\/webp"}],"author":"Gaurav Chaudhary","twitter_card":"summary_large_image","twitter_creator":"@RootsAnalysis","twitter_site":"@RootsAnalysis","twitter_misc":{"Written by":"Gaurav Chaudhary","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.rootsanalysis.com\/blog\/cell-therapy-market-update-maxcyte-advances-phase-i-clinical-trial-of-lead-mrna-based-cell-therapy\/#article","isPartOf":{"@id":"https:\/\/www.rootsanalysis.com\/blog\/cell-therapy-market-update-maxcyte-advances-phase-i-clinical-trial-of-lead-mrna-based-cell-therapy\/"},"author":{"name":"Gaurav Chaudhary","@id":"https:\/\/www.rootsanalysis.com\/blog\/#\/schema\/person\/e8e0ebc31296140424e1e7fcc11331bc"},"headline":"Cell Therapy Market Update: MaxCyte Advances Phase I Clinical Trial of Lead mRNA-based Cell Therapy","datePublished":"2019-10-25T06:59:12+00:00","dateModified":"2026-07-27T07:57:08+00:00","mainEntityOfPage":{"@id":"https:\/\/www.rootsanalysis.com\/blog\/cell-therapy-market-update-maxcyte-advances-phase-i-clinical-trial-of-lead-mrna-based-cell-therapy\/"},"wordCount":184,"publisher":{"@id":"https:\/\/www.rootsanalysis.com\/blog\/#organization"},"image":{"@id":"https:\/\/www.rootsanalysis.com\/blog\/cell-therapy-market-update-maxcyte-advances-phase-i-clinical-trial-of-lead-mrna-based-cell-therapy\/#primaryimage"},"thumbnailUrl":"https:\/\/www.rootsanalysis.com\/blog\/wp-content\/uploads\/2019\/10\/RootsAnalysis_FeaturedImage_Medical_Devices.webp","keywords":["Cell Therapy","MaxCyte"],"articleSection":["Cell Therapy"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.rootsanalysis.com\/blog\/cell-therapy-market-update-maxcyte-advances-phase-i-clinical-trial-of-lead-mrna-based-cell-therapy\/","url":"https:\/\/www.rootsanalysis.com\/blog\/cell-therapy-market-update-maxcyte-advances-phase-i-clinical-trial-of-lead-mrna-based-cell-therapy\/","name":"Cell Therapy Market Update: MaxCyte Advances Phase | Blog","isPartOf":{"@id":"https:\/\/www.rootsanalysis.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.rootsanalysis.com\/blog\/cell-therapy-market-update-maxcyte-advances-phase-i-clinical-trial-of-lead-mrna-based-cell-therapy\/#primaryimage"},"image":{"@id":"https:\/\/www.rootsanalysis.com\/blog\/cell-therapy-market-update-maxcyte-advances-phase-i-clinical-trial-of-lead-mrna-based-cell-therapy\/#primaryimage"},"thumbnailUrl":"https:\/\/www.rootsanalysis.com\/blog\/wp-content\/uploads\/2019\/10\/RootsAnalysis_FeaturedImage_Medical_Devices.webp","datePublished":"2019-10-25T06:59:12+00:00","dateModified":"2026-07-27T07:57:08+00:00","description":"MaxCyte, the global Cell Therapy, and life sciences company, announced the initiation of dosing in the third cohort of patients..","breadcrumb":{"@id":"https:\/\/www.rootsanalysis.com\/blog\/cell-therapy-market-update-maxcyte-advances-phase-i-clinical-trial-of-lead-mrna-based-cell-therapy\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.rootsanalysis.com\/blog\/cell-therapy-market-update-maxcyte-advances-phase-i-clinical-trial-of-lead-mrna-based-cell-therapy\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.rootsanalysis.com\/blog\/cell-therapy-market-update-maxcyte-advances-phase-i-clinical-trial-of-lead-mrna-based-cell-therapy\/#primaryimage","url":"https:\/\/www.rootsanalysis.com\/blog\/wp-content\/uploads\/2019\/10\/RootsAnalysis_FeaturedImage_Medical_Devices.webp","contentUrl":"https:\/\/www.rootsanalysis.com\/blog\/wp-content\/uploads\/2019\/10\/RootsAnalysis_FeaturedImage_Medical_Devices.webp","width":150,"height":150,"caption":"This is a feature image for blog article Cell Therapy Market Update at Roots Analysis"},{"@type":"BreadcrumbList","@id":"https:\/\/www.rootsanalysis.com\/blog\/cell-therapy-market-update-maxcyte-advances-phase-i-clinical-trial-of-lead-mrna-based-cell-therapy\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.rootsanalysis.com\/blog\/"},{"@type":"ListItem","position":2,"name":"Cell Therapy Market Update: MaxCyte Advances Phase I Clinical Trial of Lead mRNA-based Cell Therapy"}]},{"@type":"WebSite","@id":"https:\/\/www.rootsanalysis.com\/blog\/#website","url":"https:\/\/www.rootsanalysis.com\/blog\/","name":"Blog","description":"Roots Analysis","publisher":{"@id":"https:\/\/www.rootsanalysis.com\/blog\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.rootsanalysis.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.rootsanalysis.com\/blog\/#organization","name":"Roots Analysis","url":"https:\/\/www.rootsanalysis.com\/blog\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.rootsanalysis.com\/blog\/#\/schema\/logo\/image\/","url":"https:\/\/www.rootsanalysis.com\/blog\/wp-content\/uploads\/2018\/11\/Roots-Analysis-High-Resolution-Logo.jpg","contentUrl":"https:\/\/www.rootsanalysis.com\/blog\/wp-content\/uploads\/2018\/11\/Roots-Analysis-High-Resolution-Logo.jpg","width":205,"height":61,"caption":"Roots Analysis"},"image":{"@id":"https:\/\/www.rootsanalysis.com\/blog\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/RootsAnalysis\/","https:\/\/x.com\/RootsAnalysis","https:\/\/www.instagram.com\/rootsanalysis\/","https:\/\/www.linkedin.com\/company\/roots-analysis\/","https:\/\/www.pinterest.it\/analysis1340\/","https:\/\/www.youtube.com\/channel\/UCwZF57vY1lnU0bNLej2zukg"]},{"@type":"Person","@id":"https:\/\/www.rootsanalysis.com\/blog\/#\/schema\/person\/e8e0ebc31296140424e1e7fcc11331bc","name":"Gaurav Chaudhary","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/1661cbb4c9924618db626ec780a3daf2ebd251e93753c083102682dba715ded6?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/1661cbb4c9924618db626ec780a3daf2ebd251e93753c083102682dba715ded6?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/1661cbb4c9924618db626ec780a3daf2ebd251e93753c083102682dba715ded6?s=96&d=mm&r=g","caption":"Gaurav Chaudhary"}}]}},"_links":{"self":[{"href":"https:\/\/www.rootsanalysis.com\/blog\/wp-json\/wp\/v2\/posts\/10488","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.rootsanalysis.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.rootsanalysis.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.rootsanalysis.com\/blog\/wp-json\/wp\/v2\/users\/21"}],"replies":[{"embeddable":true,"href":"https:\/\/www.rootsanalysis.com\/blog\/wp-json\/wp\/v2\/comments?post=10488"}],"version-history":[{"count":4,"href":"https:\/\/www.rootsanalysis.com\/blog\/wp-json\/wp\/v2\/posts\/10488\/revisions"}],"predecessor-version":[{"id":22567,"href":"https:\/\/www.rootsanalysis.com\/blog\/wp-json\/wp\/v2\/posts\/10488\/revisions\/22567"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.rootsanalysis.com\/blog\/wp-json\/wp\/v2\/media\/17273"}],"wp:attachment":[{"href":"https:\/\/www.rootsanalysis.com\/blog\/wp-json\/wp\/v2\/media?parent=10488"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.rootsanalysis.com\/blog\/wp-json\/wp\/v2\/categories?post=10488"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.rootsanalysis.com\/blog\/wp-json\/wp\/v2\/tags?post=10488"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}